ICU Medical, Inc. (NASDAQ:ICUI) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank cut its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 3.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,344 shares of the medical instruments supplier’s stock after selling 170 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in ICU Medical were worth $974,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Victory Capital Management Inc. grew its stake in ICU Medical by 2,966.3% in the 2nd quarter. Victory Capital Management Inc. now owns 141,848 shares of the medical instruments supplier’s stock valued at $16,844,000 after acquiring an additional 137,222 shares during the period. Millennium Management LLC grew its position in shares of ICU Medical by 327.8% in the second quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier’s stock valued at $16,158,000 after purchasing an additional 104,264 shares during the period. FMR LLC increased its stake in shares of ICU Medical by 2,676.6% during the third quarter. FMR LLC now owns 104,094 shares of the medical instruments supplier’s stock worth $18,968,000 after purchasing an additional 100,345 shares in the last quarter. Granite Investment Partners LLC acquired a new position in shares of ICU Medical during the 2nd quarter worth about $10,650,000. Finally, F M Investments LLC purchased a new position in ICU Medical in the 2nd quarter valued at about $10,175,000. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Price Performance

ICU Medical stock opened at $155.65 on Friday. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The company has a 50-day moving average price of $173.54 and a 200 day moving average price of $148.49. ICU Medical, Inc. has a 12-month low of $83.26 and a 12-month high of $196.26. The stock has a market cap of $3.81 billion, a P/E ratio of -34.27 and a beta of 0.62.

Insider Transactions at ICU Medical

In related news, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $17,973,261.12. This represents a 10.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Christian B. Voigtlander sold 1,962 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $169.08, for a total value of $331,734.96. The disclosure for this sale can be found here. Insiders sold 40,364 shares of company stock worth $6,869,878 in the last 90 days. Insiders own 6.70% of the company’s stock.

Wall Street Analysts Forecast Growth

ICUI has been the subject of several research reports. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. Jefferies Financial Group started coverage on ICU Medical in a research report on Monday, October 14th. They set a “hold” rating and a $183.00 price target for the company. KeyCorp raised their price objective on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, November 13th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Raymond James raised their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $173.00.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.